{
    "Rank": 221,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT04696081",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "Pharmaco122020"
                },
                "Organization": {
                    "OrgFullName": "University Hospital, Caen",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Atrial Fibrillation in Active Cancer Patients",
                "OfficialTitle": "Multicenter International Prospective Registry to Identify Major Cardiovascular Events Associated With the Occurrence of Atrial Fibrillation in Active Cancer Patients",
                "Acronym": "AFIB-CANCER"
            },
            "StatusModule": {
                "StatusVerifiedDate": "June 2022",
                "OverallStatus": "Recruiting",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "September 1, 2021",
                    "StartDateType": "Actual"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "September 1, 2023",
                    "PrimaryCompletionDateType": "Anticipated"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "January 1, 2024",
                    "CompletionDateType": "Anticipated"
                },
                "StudyFirstSubmitDate": "January 4, 2021",
                "StudyFirstSubmitQCDate": "January 4, 2021",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "January 6, 2021",
                    "StudyFirstPostDateType": "Actual"
                },
                "LastUpdateSubmitDate": "September 30, 2022",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "October 3, 2022",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Sponsor"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "University Hospital, Caen",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "Groupe Hospitalier Pitie-Salpetriere",
                            "CollaboratorClass": "OTHER"
                        },
                        {
                            "CollaboratorName": "University Hospital, Marseille, France",
                            "CollaboratorClass": "UNKNOWN"
                        },
                        {
                            "CollaboratorName": "Hospices Civils de Lyon, France",
                            "CollaboratorClass": "UNKNOWN"
                        },
                        {
                            "CollaboratorName": "University of Pennsylvania, USA",
                            "CollaboratorClass": "UNKNOWN"
                        },
                        {
                            "CollaboratorName": "Centre Francois Baclesse, Caen, France",
                            "CollaboratorClass": "UNKNOWN"
                        },
                        {
                            "CollaboratorName": "Saint Antoine University Hospital, Paris, France",
                            "CollaboratorClass": "UNKNOWN"
                        },
                        {
                            "CollaboratorName": "Vanderbilt University Medical Center, USA",
                            "CollaboratorClass": "UNKNOWN"
                        },
                        {
                            "CollaboratorName": "University Hospital of Saint-Etienne, France",
                            "CollaboratorClass": "UNKNOWN"
                        },
                        {
                            "CollaboratorName": "H\u00f4pital Lariboisi\u00e8re Fernand Widal, Paris, France",
                            "CollaboratorClass": "UNKNOWN"
                        },
                        {
                            "CollaboratorName": "University Hospital, Rennes, France",
                            "CollaboratorClass": "UNKNOWN"
                        },
                        {
                            "CollaboratorName": "Hospital Universitario La Paz, Spain",
                            "CollaboratorClass": "UNKNOWN"
                        },
                        {
                            "CollaboratorName": "Institut de Canc\u00e9rologie de l'Ouest Nantes, France",
                            "CollaboratorClass": "UNKNOWN"
                        },
                        {
                            "CollaboratorName": "Fundacion Cardio Onco, Santiago, Chile",
                            "CollaboratorClass": "UNKNOWN"
                        },
                        {
                            "CollaboratorName": "Hunter New England Area Health Service, University of Newcastle, Australia",
                            "CollaboratorClass": "UNKNOWN"
                        },
                        {
                            "CollaboratorName": "Cardiology Division, University of Modena and Reggio Emilia, Policlinico di Modena, Italy",
                            "CollaboratorClass": "UNKNOWN"
                        },
                        {
                            "CollaboratorName": "Heidelberg University",
                            "CollaboratorClass": "OTHER"
                        }
                    ]
                }
            },
            "OversightModule": {
                "IsFDARegulatedDrug": "No",
                "IsFDARegulatedDevice": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "Atrial fibrillation is a common complication of both cancer and anticancer drugs but the consequences of such events remain poorly known and are not adressed in both phase III oncological trials and cardiological guidelines. The objective of this study is to create a prospective multicenter international registry of adult patients with an active cancer and experiencing atrial fibrillation to study major cardiovascular events occurrence during a 1 year follow-up."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Cancer",
                        "Drug Toxicity",
                        "Atrial Fibrillation",
                        "Cardiovascular Complication"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Observational",
                "PatientRegistry": "Yes",
                "TargetDuration": "2 Years",
                "DesignInfo": {
                    "DesignObservationalModelList": {
                        "DesignObservationalModel": [
                            "Cohort"
                        ]
                    },
                    "DesignTimePerspectiveList": {
                        "DesignTimePerspective": [
                            "Prospective"
                        ]
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "1000",
                    "EnrollmentType": "Anticipated"
                }
            },
            "ArmsInterventionsModule": {
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Other",
                            "InterventionName": "occurence of atrial fibrillation",
                            "InterventionDescription": "all adult patients with an active cancer and experiencing atrial fibrillation will be consecutively include. Active cancers will be defined according Agnelli et al. (NEJM 2020; 382:1599-1607)."
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Occurrence of major cardiovascular events and death of any cause at 1 year",
                            "PrimaryOutcomeDescription": "Occurrence of death of any cause, cardiovascular death, heart failure, stroke, myocardial infarction in active cancer patients with atrial fibrillation.",
                            "PrimaryOutcomeTimeFrame": "from inclusion in the registry to 1 year of follow-up"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Occurrence of major cardiovascular events and death of any cause at 1 year in prevalent and incident AF patients",
                            "SecondaryOutcomeDescription": "Occurrence of death of any cause, cardiovascular death, heart failure, stroke, myocardial infarction in active cancer patients according to the AF type (prevalent or incident).",
                            "SecondaryOutcomeTimeFrame": "from inclusion in the registry to 1 year of follow-up"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Description of the population of active cancer patients experiencing atrial fibrillation (in both prevalent and incidence AF patients).",
                            "SecondaryOutcomeDescription": "Description of the population of active cancer patients experiencing atrial fibrillation. Active cancers will be defined according Agnelli et al. (NEJM 2020; 382:1599-1607).",
                            "SecondaryOutcomeTimeFrame": "at the inclusion in the registry"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Description of the management of atrial fibrillation in cancer patients (in both prevalent and incidence AF patients).",
                            "SecondaryOutcomeDescription": "Description of the management (anticoagulants, rhythm or rate control) of atrial fibrillation in cancer patients",
                            "SecondaryOutcomeTimeFrame": "from inclusion in the registry to 1 year of follow-up"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Description of the population of active cancer patients having a major cardiovascular event",
                            "SecondaryOutcomeDescription": "Description of the population of patients having a major cardiovascular event among cancer patients experiencing atrial fibrillation",
                            "SecondaryOutcomeTimeFrame": "from inclusion in the registry to 1 year of follow-up"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Identifying risk factors associated with major cardiovascular events and all cause mortality occurrence",
                            "SecondaryOutcomeDescription": "Identifying risk factors (clinical, EKG, biological, echocardiography) of major cardiovascular events and all cause mortality in cancer patients experiencing atrial fibrillation",
                            "SecondaryOutcomeTimeFrame": "from inclusion in the registry to 1 year of follow-up"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Identifying factors associated with atrial fibrillation recurrence",
                            "SecondaryOutcomeDescription": "Identifying factors (clinical, EKG, biological, echocardiography) of atrial fibrillation recurrence in cancer patients",
                            "SecondaryOutcomeTimeFrame": "from inclusion in the registry to 1 year of follow-up"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Occurrence of major and clinically relevant non-major bleedings (2005 ISTH definition)",
                            "SecondaryOutcomeDescription": "Occurrence of major and clinically relevant non-major bleedings in active cancer patients experiencing atrial fibrillation.",
                            "SecondaryOutcomeTimeFrame": "from inclusion in the registry to 1 year of follow-up"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Identifying risk factors associated with major and clinically relevant non-major bleedings (2005 ISTH definition)",
                            "SecondaryOutcomeDescription": "Identifying risk factors (clinical, EKG, biological, echocardiography) of major and clinically relevant non-major bleedings in active cancer patients experiencing atrial fibrillation",
                            "SecondaryOutcomeTimeFrame": "from inclusion in the registry to 1 year of follow-up"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nadult patients\noutpatients or hospitalized patients\nwith a confirmed cancer (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor, known intracerebral metastases, or acute leukemia) and an active cancer (defined as cancer that had been diagnosed within the past 6 months or recurrent locally advanced or metastatic cancer, for which anticancer treatment was being given at the time of enrollment or during 6 months before enrollment)\nat least 1 episode of atrial fibrillation (new onset AF occuring after cancer diagnosis or history of paroxysmal of persistant AF prior to cancer diagnosis and an AF recurrence after cancer diagnosis)\nin sinus rhythm at the time of cancer diagnosis\n\nExclusion Criteria:\n\npatient with palliative cares or other conditions resulting in short term death (death expected in the month following atrial fibrillation occurrence)\nhistory of long-standing persistant or permanent AF prior to cancer diagnosis",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                },
                "StudyPopulation": "Patients with a cancer will defined as patients with confirmed cancer other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor, known intracerebral metastases, or acute leukemia.\n\nActive cancer will be defined as cancer that had been diagnosed within the past 6 months or recurrent locally advanced or metastatic cancer, and an anticancer treatment given at the time of enrollment or during 6 months before enrollment (according to Agnelli et al. NEJM 2020).\n\nAF patients will be both patients with incident AF (first AF episode diagnosed after cancer diagnosis) and those with prevalent AF (AF recurrence occurring after cancer diagnosis and a first AF episode prior to cancer diagnosis)",
                "SamplingMethod": "Non-Probability Sample"
            },
            "ContactsLocationsModule": {
                "CentralContactList": {
                    "CentralContact": [
                        {
                            "CentralContactName": "Joachim Alexandre, MD, PhD",
                            "CentralContactRole": "Contact",
                            "CentralContactPhone": "+330231064770",
                            "CentralContactEMail": "alexandre-j@chu-caen.fr"
                        }
                    ]
                },
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Joachim Alexandre, MD, PhD",
                            "OverallOfficialAffiliation": "Caen Normandy University Hospital, France",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Alexandre",
                            "LocationStatus": "Recruiting",
                            "LocationCity": "Caen",
                            "LocationState": "Normandy",
                            "LocationZip": "14000",
                            "LocationCountry": "France",
                            "LocationContactList": {
                                "LocationContact": [
                                    {
                                        "LocationContactName": "Joachim ALEXANDRE, MD, PhD",
                                        "LocationContactRole": "Contact"
                                    },
                                    {
                                        "LocationContactRole": "Contact",
                                        "LocationContactEMail": "alexandre-j@chu-caen.fr"
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "ReferencesModule": {
                "ReferenceList": {
                    "Reference": [
                        {
                            "ReferencePMID": "29698683",
                            "ReferenceType": "background",
                            "ReferenceCitation": "Alexandre J, Moslehi JJ, Bersell KR, Funck-Brentano C, Roden DM, Salem JE. Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms. Pharmacol Ther. 2018 Sep;189:89-103. doi: 10.1016/j.pharmthera.2018.04.009. Epub 2018 Apr 24."
                        },
                        {
                            "ReferencePMID": "32353110",
                            "ReferenceType": "background",
                            "ReferenceCitation": "Alexandre J, Salem JE, Moslehi J, Sassier M, Ropert C, Cautela J, Thuny F, Ederhy S, Cohen A, Damaj G, Vilque JP, Plane AF, Legallois D, Champ-Rigot L, Milliez P, Funck-Brentano C, Dolladille C. Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur Heart J Cardiovasc Pharmacother. 2021 Jul 23;7(4):312-320. doi: 10.1093/ehjcvp/pvaa037."
                        }
                    ]
                }
            },
            "IPDSharingStatementModule": {
                "IPDSharing": "Undecided"
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000001281",
                            "ConditionMeshTerm": "Atrial Fibrillation"
                        },
                        {
                            "ConditionMeshId": "D000064420",
                            "ConditionMeshTerm": "Drug-Related Side Effects and Adverse Reactions"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000001145",
                            "ConditionAncestorTerm": "Arrhythmias, Cardiac"
                        },
                        {
                            "ConditionAncestorId": "D000006331",
                            "ConditionAncestorTerm": "Heart Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000002318",
                            "ConditionAncestorTerm": "Cardiovascular Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000010335",
                            "ConditionAncestorTerm": "Pathologic Processes"
                        },
                        {
                            "ConditionAncestorId": "D000064419",
                            "ConditionAncestorTerm": "Chemically-Induced Disorders"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M4276",
                            "ConditionBrowseLeafName": "Atrial Fibrillation",
                            "ConditionBrowseLeafAsFound": "Atrial Fibrillation",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M29993",
                            "ConditionBrowseLeafName": "Drug-Related Side Effects and Adverse Reactions",
                            "ConditionBrowseLeafAsFound": "Drug Toxicity",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M4143",
                            "ConditionBrowseLeafName": "Arrhythmias, Cardiac",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M9109",
                            "ConditionBrowseLeafName": "Heart Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M29992",
                            "ConditionBrowseLeafName": "Chemically-Induced Disorders",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC14",
                            "ConditionBrowseBranchName": "Heart and Blood Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC23",
                            "ConditionBrowseBranchName": "Symptoms and General Pathology"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC25",
                            "ConditionBrowseBranchName": "Substance Related Disorders"
                        }
                    ]
                }
            }
        }
    }
}